Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637997 | 0.87 | MEN1 (0.44) | MEN1KMT2AMAPTATMKDM4E | |
| SCHEMBL27841858 | 0.84 | MEN1 (0.44) | MEN1KMT2AMAPTATMKDM4E | |
| SCHEMBL11162976 | 0.83 | MEN1 (0.37) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL11428301 | 0.82 | USP2 (0.44) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL18051907 | 0.82 | MEN1 (0.48) | MEN1KMT2AMAPTATMKDM4E | |
| SCHEMBL11152882 | 0.77 | MEN1 (0.32) | MEN1KMT2AMAPTATMPOLB | |
| SCHEMBL3964702 | 0.74 | PIK3CD (0.33) | MEN1KMT2AKDM4E | |
| SCHEMBL12712788 | 0.74 | KMT2A (0.39) | MEN1KMT2AMAPTATMKDM4E | |
| SCHEMBL4876041 | 0.74 | L3MBTL1 (0.42) | MEN1KMT2AMAPTATMPOLB | |
| SCHEMBL7904700 | 0.74 | L3MBTL1 (0.40) | MEN1KMT2AMAPTKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457898-A1 | FULLERENE DERIVATIVE | Sumitomo Chemical Company Limited (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20120111411-A1 | FULLERENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120111411-A1 | FULLERENE DERIVATIVE | HCN2, KCNN2, TMEM109 | MEN1 748/4885KMT2A 2633/4885MAPT 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.